madman
Super Moderator
* Randomized trials in obese hypogonadal men showed benefits including increased muscle mass, reduced fat, higher HDL, improved erectile function, and elevated TT. Older age (>55 years) was linked to reduced androgenic response. In late-onset hypogonadism, CC discontinuation led to relapse, though long-term use (up to 52 months) proved safe and effective.
* Preserved testicular volume, LH ≤6 IU/L, and younger age appear favorable. Further research is needed to clarify the role of prolactin and other functional markers in treatment selection.
Abstract
Introduction and Objectives
Clomiphene citrate (CC) is a safe and effective alternative to exogenous testosterone therapy for men with hypogonadism, particularly those wishing to preserve fertility. It maintains hypothalamic–pituitary-gonadal axis function and offers oral administration at a lower cost. Although 70–75% of patients experience significant increases in total testosterone (TT), reliable predictors of response remain unclear. This review aimed to identify clinical and biochemical factors associated with CC responsiveness.
Methods
A narrative review was conducted using PubMed and Medline. Clinical studies evaluating CC use in hypogonadal men and analyzing predictors of biochemical response were included.
Results
In a cohort of 332 men, the mean TT increase was 329 ng/dL, with 73% achieving ≥200 ng/dL. However, baseline LH and FSH levels showed inconsistent correlation with outcomes. Mazzola et al. identified testicular volume ≥ 14 mL and LH ≤6 IU/L as independent predictors of robust response. Hammami et al. found higher prolactin levels associated with improved semen parameters in men with idiopathic oligo- zoospermia. Randomized trials in obese hypogonadal men showed benefits including increased muscle mass, reduced fat, higher HDL, improved erectile function, and elevated TT. Older age (>55 years) was linked to reduced androgenic response. In late-onset hypogonadism, CC discontinuation led to relapse, though long-term use (up to 52 months) proved safe and effective.
Conclusion
Despite its efficacy, identifying strong predictors of CC response remains challenging. Preserved testicular volume, LH ≤6 IU/L, and younger age appear favorable. Further research is needed to clarify the role of prolactin and other functional markers in treatment selection.
* Preserved testicular volume, LH ≤6 IU/L, and younger age appear favorable. Further research is needed to clarify the role of prolactin and other functional markers in treatment selection.
Abstract
Introduction and Objectives
Clomiphene citrate (CC) is a safe and effective alternative to exogenous testosterone therapy for men with hypogonadism, particularly those wishing to preserve fertility. It maintains hypothalamic–pituitary-gonadal axis function and offers oral administration at a lower cost. Although 70–75% of patients experience significant increases in total testosterone (TT), reliable predictors of response remain unclear. This review aimed to identify clinical and biochemical factors associated with CC responsiveness.
Methods
A narrative review was conducted using PubMed and Medline. Clinical studies evaluating CC use in hypogonadal men and analyzing predictors of biochemical response were included.
Results
In a cohort of 332 men, the mean TT increase was 329 ng/dL, with 73% achieving ≥200 ng/dL. However, baseline LH and FSH levels showed inconsistent correlation with outcomes. Mazzola et al. identified testicular volume ≥ 14 mL and LH ≤6 IU/L as independent predictors of robust response. Hammami et al. found higher prolactin levels associated with improved semen parameters in men with idiopathic oligo- zoospermia. Randomized trials in obese hypogonadal men showed benefits including increased muscle mass, reduced fat, higher HDL, improved erectile function, and elevated TT. Older age (>55 years) was linked to reduced androgenic response. In late-onset hypogonadism, CC discontinuation led to relapse, though long-term use (up to 52 months) proved safe and effective.
Conclusion
Despite its efficacy, identifying strong predictors of CC response remains challenging. Preserved testicular volume, LH ≤6 IU/L, and younger age appear favorable. Further research is needed to clarify the role of prolactin and other functional markers in treatment selection.
